


Express Mail No.: EL615430881US

01-2204
Date Mailed: January 20, 2004



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jose L. BOYER, *et al.*

Appl. No. 09/643,138

Filed: August 21, 2000

For: COMPOSITION AND METHOD FOR
INHIBITING PLATELET
AGGREGATION

5034
Confirmation No.: 8780

Art Unit: 1623

Examiner: Owens, Jr., Howard V.

Atty. Docket: 03678.0064.00US00

1625
RECEIVED
JAN 28 2004
TECH CENTER 1600/2900

Supplemental Information Disclosure Statement

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

01/26/2004 HROCHA1 00000039 09643138

01 FC:1006

100.00 OP

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not

exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- ☐ 1. This Information Disclosure Statement is being filed;
- ☐ a. Within three months of the U.S. filing date of a national application other than a continued prosecution application under §1.53(d);
 - ☐ b. Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
 - ☐ c. Before the mailing date of a first Office Action on the merits;
 - ☐ d. Before the mailing of a first Office Action after filing of a request for continued examination under § 1.115.

No statement under 37 C.F.R. § 1.97(e) or fee is required.

or;

- ☒ 2. This Information Disclosure Statement is being filed after the period specified in paragraph 1(a)-1(d) above, but before the mailing date of a Final Rejection or Notice of Allowance, or action that otherwise closes prosecution in the application, and
- ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
 - ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c)

more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2), or

- ☒ c. Attached is our check in the amount of \$ 180.00 in payment of the fee under 37 C.F.R. § 1.17(p).
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but on or before payment of the Issue Fee. Attached is our Check No. _____ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(i), and
 - ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
 - ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- ☐ 4. Relevance of the non-English language document(s) is discussed in the present specification.
- ☐ 5. The document(s) was/were cited in a corresponding foreign application. An English language version of the foreign search report is attached for the Examiner's information.
- ☐ 6. A concise explanation of the relevance of the non-English language document(s) appears below:
- ☐ 7. The Examiner's attention is directed to co-pending U.S. Patent Application No. _____, filed _____, which is directed to related technical subject matter.


The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.

- ☐ 8. Copies of the documents were cited by or submitted to the Office in Application No. _____, filed _____, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.


The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038 referencing docket number 03678.0064.00US00.

Respectfully submitted,


Albert P. Halluin, Reg. No. 25,227
Viola T. Kung, Reg. No. 41,131

Date: January 20, 2004

HOWREY SIMON ARNOLD & WHITE, LLP
Box No. 34
301 Ravenswood Avenue
Menlo Park, CA 94025
(650) 463-8109



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) PTO FORM 1449		ATTY. DOCKET NO.	APPLICATION NO.
		03678.0064.00US00	09/643,138
APPLICANT			
Boyer, et al.			
FILING DATE		GROUP	
21-Aug-2000		1623	

U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	1.							
	2.							
	3.							
	4.							
FOREIGN PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	5.	WO 92/ 01673	07/11/91					
	6.							
	7.							
OTHER REFERENCES								
(Including Author, Title, Date, Pertinent Pages, Etc.)								
	8.	Alessi, D. <i>et al.</i> , "Synthesis and Properties of a Conformationally Restricted Spin-Labeled Analog of ATP and Its Interaction with Myosin and Skeletal Muscle" <i>Biochemistry</i> (1992), 31(34), 8043-54.						
	9.	Bujalowski, W. <i>et al.</i> , "Structural Characteristics of the Nucleotide-Binding Site of <i>Escherichia coli</i> Primary Replicative Helicase DnaB Protein. Studies with Ribose and Base-Modified Fluorescent Nucleotide Analogs" <i>Biochemistry</i> (1994), 33(15), 4682-94.						
	10.	Cardullo, R. A. <i>et al.</i> , "Synthesis, Purification, and Characterization of 2,4,6-Trinitrophenyl-UDP-galactose: A Fluorescent Substrate for Galactosyltransferase" <i>Analytical Biochemistry</i> (1990), 188(2), 305-9.						
	11.	Carvalho-Alves, P. <i>et al.</i> , "Stoichiometric Photolabeling of Two Distinct Low and High Affinity Nucleotide Sites in Sarcoplasmic Reticulum ATPase" <i>Journal of Biological Chemistry</i> (1985), 260(7), 4282-7.						
	12.	Chapal, J. <i>et al.</i> , "Comparative effects of adenosine-5'-triphosphate and related analogs on insulin secretion from the rat pancreas" <i>Fundamental & Clinical Pharmacology</i> (1997), 11(6), 537-545.						
	13.	Hiratsuka, Toshiaki, "Biological Activities and Spectroscopic Properties of Chromophoric and Fluorescent Analogs of Adenine Nucleoside and Nucleotides, 2',3'-O-(2,4,6-Trinitrocyclohexadienylidene) Adenosine Derivatives" <i>Biochimica et Biophysica Acta</i> (1982), 719(3), 509-17.						
	14.	Hiratsuka, Toshiaki, "Monitoring the Myosin ATPase Reaction Using a Sensitive Fluorescent Probe: Pyrene-Labeled ATP" <i>Biophysical Journal</i> (1997), 72(2, Pt. 1), 843-849.						


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) PTO FORM 1449	ATTY. DOCKET NO. 03678.0064.00US00	APPLICATION NO. 09/643,138
	APPLICANT Boyer, et al.	
	FILING DATE 21-Aug-2000	GROUP 1623

15.	Ikehara, M. <i>et al.</i> , "III. Interaction Between Synthetic Adenosine Triphosphate Analogs and Actomyosin Systems" <i>Biochimica et Biophysica Acta</i> (1965), 100(2), 471-8.
16.	Ikehara, M. <i>et al.</i> , "Unusual Rapid Cleavage of Terminal Phosphate Group of N6-Disubstituted Adenosine 5'-Triphosphate (ATP) by Divalent Cation" <i>Biochimica et Biophysica Acta</i> (1964), 85(3), 512-515.
17.	Kwiatkowski, A. <i>et al.</i> , "Mapping of the Adenosine 5'-Triphosphate Binding Site of Type II Calmodulin-Dependent Protein Kinase" <i>Biochemistry</i> (1987), 26(24), 7636-40.
18.	Lowe, G. <i>et al.</i> , "Evidence of a Dissociative S _N 1(P) Mechanism of Phosphoryl Transfer by Rabbit Muscle Pyruvate Kinase" <i>Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry</i> (1972-1999) (1978), (12), 1622-30.
19.	Marian, M., "Acetyl Derivatives of Nucleoside 5'-Triphosphates. I." <i>Microchemical Journal</i> (1984), 29(2), 219-27.
20.	Mayer, I. <i>et al.</i> , "Interaction of Fluorescent Adenine Nucleotide Derivatives with the ADP/ATP Carrier in Mitochondria. 1. Comparison of Various 3'-O-Ester Adenine Nucleotide Derivatives" <i>Biochemistry</i> (1984), 23(11), 2436-42.
21.	Murataliev, M. <i>et al.</i> , "Interaction of mitochondrial F ₁ -ATPase with trinitrophenyl derivatives of ATP. Photoaffinity labeling of binding sites with 2-azido-2',3'-O-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate" <i>European Journal of Biochemistry</i> (1995), 232(2), 578-85.
22.	Oliveira, C. R. G. <i>et al.</i> , "Interaction of Spin-Labeled Nucleotides with Sarcoplasmic Reticulum Adenosinetriphosphatase" <i>Biochemistry</i> (1988), 27(16), 5923-7.
23.	Ray, S. <i>et al.</i> , "Microenvironment at the Substrate Binding Subsite of the Active Site of UDPglucose 4-Epimerase from <i>Kluyveromyces Fragilis</i> Using a Fluorescent Analog of UMP" <i>Indian Journal of Biochemistry & Biophysics</i> (1992), 29(2), 209-13.
24.	Seebregts, C. <i>et al.</i> , "2',3'-O-(2,4,6-Trinitrophenyl)-8-Azido-adenosine Mono-, Di-, and Triphosphates as Photoaffinity Probes of the Ca ²⁺ -ATPase of Sarcoplasmic Reticulum. Regulatory/Superfluorescent Nucleotides Label the Catalytic Site with High Efficiency" <i>Journal of Biological Chemistry</i> (1989), 264(4), 2043-52.
25.	Soslau, G. <i>et al.</i> , "Aggregation of Human and Canine Platelets: Modulation by Purine Nucleotides" <i>Thrombosis Research</i> (1993), 72(2), 127-37.
26.	Thoenges D. <i>et al.</i> , "Tight Binding of Bulky Fluorescent Derivatives of Adenosine to the Low Affinity E ₂ ATP Site Leads to Inhibition of Na ⁺ /K ⁺ -ATPase. Analysis of Structural Requirements of Fluorescent ATP Derivatives with a Koshland-Nemethy-Filmer Model of Two Interacting ATP Sites" <i>Journal of Biological Chemistry</i> (1999 Jan 22), 274(4), 1971-8.
27.	Vigne, P. <i>et al.</i> , "Benzoyl ATP Is an Antagonist of Rat and Human P2Y ₁ Receptors and of Platelet Aggregation" <i>Biochemical and Biophysical Research Communications</i> (1999), 256(1), 94-97.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET NO.

03678.0064.00US00

APPLICATION NO.

09/643,138

APPLICANT

Boyer, et al.

FILING DATE

21-Aug-2000

GROUP

1623

	28.	Ward, D. <i>et al.</i> , "Photoinactivation of Fluorescein Isothiocyanate-modified Na,K-ATPase by 2'(3')-O-(2,4,6-Trinitrophenyl)8-azidoadenosine 5'-Diphosphate. Abolition of E1 and E2 Partial Reactions by Sequential Block of High and Low Affinity Nucleotide Sites" <i>Journal of Biological Chemistry</i> (1998), 273(23), 14277-14284.
--	-----	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.